Elimination of Tumor Suppressor Proteins during Liver Carcinogenesis
Journal Title: Cancer Studies & Molecular Medicine – Open Journal - Year 2014, Vol 1, Issue 1
Abstract
Liver cancer is one of the most lethal cancers. Quiescent liver expresses up to 20 tumor suppressor proteins including Rb, p53, CCAAT-Enhancer-Binding Protein (C/EBP)α, Hepatocyte Nuclear Factor (HNF4)α and p16 and it is well protected from development of liver cancer. However, the negative control of liver proliferation by these factors and other tumor suppressor genes is eliminated in liver cancer. Studies of liver regeneration after surgery and injury have provided fundamental mechanisms on how liver neutralizes tumor suppressor proteins for the time of regeneration; however, studies of liver cancer in animal models and in human samples showed several additional pathways of this neutralization. One of these additional pathways includes activation of a small subunit of the proteasome, Gankyrin. Gankyrin is dramatically increased in human hepatocellular carcinoma (HCC) and in animal models of carcinogenesis. Once activated Gankyrin triggers degradation of main tumor suppressor proteins during development of liver cancer using slightly different mechanisms. Recent studies identified mechanisms which repress Gankyrin in quiescent livers and mechanisms of activation of Gankyrin in liver cancer. These mechanisms involve a communication between Farnesoid X Receptor (FXR) signaling and chromatin remodelling proteins mediated by members of C/EBP family. It has been recently shown that C/EBPα plays a critical role in this network and that the activation of C/EBPα in cirrhotic livers with HCC inhibits cancer progression. This C/EBPαdependent inhibition of liver cancer involves activation of a majority of tumor suppressor genes and repression of tumor initiating pathways such as β-catenin and c-myc. These recent findings provide a background for FXR-based and C/EBPα-based approaches to treat liver cancer.
Authors and Affiliations
Nikolai A. Timchenko
Keywords
Related Articles
- EP ID EP552522
- DOI 10.17140/CSMMOJ-1-104
- Views 124
- Downloads 0
Elimination of Tumor Suppressor Proteins during Liver Carcinogenesis
Liver cancer is one of the most lethal cancers. Quiescent liver expresses up to 20 tumor suppressor proteins including Rb, p53, CCAAT-Enhancer-Binding Protein (C/EBP)α, Hepatocyte Nuclear Factor (HNF4)α and p16 and it is...
Prostate Cancer Trends in Developing Countries
Prostate cancer is the commonest cancer in USA and most European Countries and is the 2nd commonest cancer among males globally. An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012, account...
Is it Time to Start Using Mitochondrial DNA Copy Number as an Indicator of Health and Diseases?
Clinical biochemistry and pathology have contributed too many assays for diagnosis and prognosis of human health and diseases. Bedside biochemistry has revolutionized modern medicine and the invention of new generation b...
Long Term, Low Dose Genistein decreases Stem Cell Populations and Sensitizes Inflammatory Breast Cancer Cell Lines to Radiation
Local recurrence in inflammatory breast cancer is common and is associated with poor prognosis. Recurrence is driven by a small population of radioresistant breast cancer cells that have stem-like properties. Previous st...
Flavones and Flavonols may have Clinical Potential as CK2 Inhibitors in Cancer Therapy
The serine-threonine kinase CK2, which targets over 300 cellular proteins, is over expressed in all cancers, presumably reflecting its ability to promote proliferation, spread, and survival through a wide range of comple...